Low risk of viral hepatitis amongst patients with severe mental disorders

Liver Int. 2023 Jun;43(6):1204-1212. doi: 10.1111/liv.15569. Epub 2023 Apr 11.

Abstract

Background and aims: Patients with severe mental disorders (SMD) have been classically considered as a particularly high-risk population for bloodborne virus infections. We performed a systematic screening of hepatitis B and C virus among the population with SMD in the area of influence of Hospital Clínic (Barcelona) in order to evaluate the real prevalence of these infections and achieve HCV microelimination in this subpopulation.

Methods: We screened two cohorts for anti-HCV and HBsAg: Cohort A (hospitalized patients with SMD, done systematically) and Cohort B (outpatients, mental health centre-CSMA, done voluntarily). Risk factors and socio-demographic variables were collected. In positive cases, telematic review was activated by Hepatology, calculation of FIB-4 and prescription of direct-acting agents (DAA) in HCV or follow-up in HBV.

Results: In Cohort A, 404 patients were screened. 3 HBV patients were detected (0.7%). In all of them, there was a history of drug use. 12 anti-HCV positive patients were detected (3%); 8 of them had a history of drug use. Among the HCV positive, only 2 patients were viraemic (received DAA, both achieving SVR) as most of them (n = 6) had already been cured with DAA. In cohort B, 305 patients were screened, after 542 (64% of the target population) declined to participate. No cases of HCV or HBV were detected.

Conclusions: HCV/HBV prevalence among SMD population with no history of drug use does not seem to be different from the general population. These data may be of interest for defining health policies.

Keywords: dual disorders; microelimination; psychiatric population; severe mental disorders; viral hepatitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • Hepatitis B Surface Antigens
  • Hepatitis B virus
  • Hepatitis B* / complications
  • Hepatitis B* / drug therapy
  • Hepatitis B* / epidemiology
  • Humans
  • Mental Disorders* / complications
  • Mental Disorders* / drug therapy
  • Mental Disorders* / epidemiology

Substances

  • Antiviral Agents
  • Hepatitis B Surface Antigens